期刊文献+

替加色罗联合氟哌噻吨美利曲辛治疗功能性消化不良的临床评价

Clinic evaluation on function dyspepsia treated with tagaserod combined with flupentixolmelitracen
下载PDF
导出
摘要 目的探讨替加色罗联合氟哌噻吨美利曲辛治疗功能性消化不良(FD)的临床疗效。方法132例FD患者均经汉密尔顿焦虑量表(HAMA)和汉密尔顿抑郁量表(HAMD)进行精神心理学评定诊断为精神心理异常,用配对分组法分为治疗组、对照组各66例,治疗组给予替加色罗联合氟哌噻吨美利曲辛治疗,对照组给予奥美拉唑和莫沙必利治疗,疗程为4周。4周后重新评定上述量表总分和临床症状缓解情况,并进行评价和对比。结果两组消化道症状改善总有效率分别为90.9%、65.2%,组间比较差异有统计学意义(P〈0.01);治疗组精神量表总分治疗前后比较差异有统计学意义(P〈0.01),对照组差异无统计学意义(P〉0.05)。结论替加色罗联合氟哌噻吨美利曲辛治疗FD对缓解消化道症状和改善心理异常疗效显著,FD患者的消化道症状与精神心理因素有关。 Objective To observe the clinical efficacy of tagaserod combined with flupentixolmelitraeen to treat patients with function dyspepsia (FD). Methods One hundred and twelve patients with FD were evaluated to be psychological abnormal with Hamihom anxiety scale (HAMA) and Hamihom depression rating scale (HAMD), and were divided into therapy group and control group according to a case-control study. Sixty-six eases of therapy group were treated with tagaserod combined with flupentixolmelitracen for 4 weeks, 66 cases of control group were treated with omeprazole combined with mosapride for 4 weeks. All were evaluated again with HAMA and HAMD after treatment, clinical symptom and efficacy were compared between two groups. Results The effective rates were 90.9% in therapy group and 65.2% in control group (P〈 0.01 ). The scores of psychological scales in therapy group were significant difference between before and after treatment (P 〈 0.01), those in control group were no difference (P 〉 0.05). Conclusion Tagaserod combined with tlupentixolmelitracen is notably effective on FD. Digestive symptoms in patients with FD are related to psychological factors.
出处 《中国医师进修杂志(内科版)》 2007年第2期40-41,共2页 Chinese Journal of Postgraduates of Medicine
关键词 功能性消化不良 精神心理异常 替加色罗 氟哌噻吨美利曲辛 Function dyspepsia Psychological abnormal Tagaserod Flupentixolmelitracen
  • 相关文献

参考文献5

二级参考文献37

  • 1侯晓华.功能性胃肠疾病与内脏感觉过敏[J].基础医学与临床,2003,23(z1):6-7. 被引量:15
  • 2李增烈.消化不良的临床流行病学[J].中国实用内科杂志,1995,15(1):5-6. 被引量:73
  • 3[1]Telley NJ,Camilleri M. Epidemiological feature of functional dyspepsia and irritable bowel sydrome. Clinician, 1996,14(1):7~13
  • 4[3]Talley NJ,Stanghellini V,Heading RC,et al. Functional gastroduodenal disorders. Gut, 1999,45 (suppl 2): 37~42
  • 5[6]Drossman DA. Gastrointestinal illness and the biopsychosocial model. J Clin Gasroenterol, 1996,22 (4): 252~254
  • 6[8]Wilhelmsen I, Haug TT, Ursin H, et al. Discriminae analysis of factor distinguishing patients with functional dyspepsia from patients with duodenal ulcer. Dig Dis Sci,1995,40(5):1105~1110
  • 7[10]Tanum L,Malt UF. A new pharmacological treatment of functional gastrointestinal disorder: a double-blind placebo-controlled study with mianserin. Scand J Gastroenterol, 1996,31 (4): 318~ 325
  • 8Talley NJ, Zinsmeister AR, Schleck CD, et al. Dyspepsia and dyspepsias ubgroups: A population-based study[J]. Gastroenterology, 1992,102(4Pt1):1259.
  • 9Malagelada JR. Manometric evaluation of functional upper gut symptoms[J]. Gastroenterology, 1985,88( 1 ) : 123.
  • 10Pieramico O. Gastrointestinal motility in Patients with nonulcer dyspepsia; a role for Helicobacter pylori infection[J]. Gastroenterol, 1993,88(3):364.

共引文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部